By Fineline Cube 
Degron Therapeutics, a China‑based pioneer in protein‑degradation therapies, today announced the signing of a Letter of Intent for Cooperation with MSD R&D (China) Co., Ltd. The partnership will focus on the joint development of a first‑in‑class molecular glue degrader currently in Degron’s pipeline.
Partnership Highlights
| Element | Detail |
|---|---|
| Letter of Intent Date | 11 Nov 2025 |
| Collaborating Parties | Degron Therapeutics & MSD R&D (China) |
| Co‑Development Focus | First‑in‑class molecular glue degrader |
| Strategic Fit | Leverage Degron’s GlueXplorer platform and MSD’s clinical expertise in oncology and rare diseases |
About Degron Therapeutics
Degron Therapeutics specializes in novel protein‑degradation therapeutics—molecular glue small molecules—powered by its globally leading GlueXplorer drug‑discovery platform. The platform offers:
- Independently curated compound library with unique scaffold chemistry and proprietary protection mechanisms.
- High‑throughput screening and validation system that targets disease pathways previously deemed undruggable.
- A proven pipeline of small‑molecule degraders aimed at critical therapeutic indications, from oncology to neurodegeneration.
Strategic Significance
- Accelerated Innovation – The alliance will synergize Degron’s discovery capabilities with MSD’s expansive R&D roadmap, hastening the trajectory toward clinical candidates.
- Expanded Therapeutic Scope – By harnessing molecular glue technology, the partnership aims to unlock treatment options for challenging targets, potentially reshaping the landscape of druggable proteins.
- Market Positioning – Combined strength positions the collaborators at the forefront of next‑generation protein‑degradation therapies, appealing to investors and partners seeking high‑impact treatments.
Forward‑Looking Statements
This communication contains forward‑looking statements. Actual results may differ materially.-Fineline Info & Tech